The 42 references in paper D. Lukyantseva V., L. Mel’nikova S., A. Tatarinov P., Д. Лукьянцева В., Л. Мельникова С., А. Татаринов П. (2018) “МЕЖДУНАРОДНЫЙ ОПЫТ ЛЕКАРСТВЕННОГО ОБЕСПЕЧЕНИЯ НАСЕЛЕНИЯ В АМБУЛАТОРНОМ СЕКТОРЕ // THE INTERNATIONAL PRACTICE OF DRUG SUPPLY IN THE OUTPATIENT SEGMENT” / spz:neicon:pharmacoeconomics:y:2017:i:4:p:44-52

1
Pharmaceutical Financing Strategies. (MDS-3: Managing Access to Medicines and Health Technologies, Chapter 11), (2012; 18 pages). URL: http://apps.who.int/medicinedocs/documents/s19587en/ s19587en.pdf. Accessed: 25.10.2017.
(check this in PDF content)
2
World health report: Financing of health systems: A path to universal coverage of health care; World Health Organization 2010 (in Russian). URL: http://www.who.int/whr/2010/whr10_ru.pdf?ua=1. Accessed: 25.10.2017.
(check this in PDF content)
3
Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 41. URL: http://www.euro.who.int/__ data/assets/pdf_file/0016/314404/HIT_Netherlands.pdf. Accessed: 25.10.2017.
(check this in PDF content)
4
Geneesmiddelenbulletin. The role of drug bulletins. Retrieved from http://geneesmiddelenbulletin.com/english/the-role-of-drugbulletins/. Accessed: 25.10.2017.
(check this in PDF content)
5
Specialisten schrijven specialistisch voor [Specialists prescribe specialist pharmaceuticals]. Pharmaceutisch Weekblad. 2003; 138 (17): 1. URL: http://www.sfk.nl/nieuws-publicaties/PW/2014/opnieuwminder-apotheken. Accessed: 25.10.2017.
(check this in PDF content)
6
Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 275. URL: http://www.euro.who.int/__data/assets/pdf_ file/0016/314404/HIT_Netherlands.pdf. Accessed: 25.10.2017.
(check this in PDF content)
7
Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 149-150. URL: http://www.euro.who.int/__ data/assets/pdf_file/0016/314404/HIT_Netherlands.pdf. Accessed: 25.10.2017.
(check this in PDF content)
8
Griens A. M.G.F., Janssen J. M., Kroon J. D.L., Lukaart J. S., van der Vaart R. J. Data en feiten 2015. Het jaar 2014 in cijfers [Data and facts 2015. The year 2014 in figures]. The Hague: Stichting Farmaceutische Kengetallen (SFK). URL: https://www.sfk.nl/ publicaties/data-en-feiten/data-en-feiten-2015/view. Accessed: 25.10.2017.
(check this in PDF content)
9
Prins M. A., Hek K., Verberne L., Nielen M., Opperhuizen G., Verheij R. Zorg door de huisarts: jaarcijfers 2014 en trendcijfers 20102014 [Care provided by the GP, annual figures 2014 and trend figures 2010-2014]. URL: https://www.nivel.nl/sites/default/files/bestanden/ dietist_jaarcijfers_2014.pdf. Accessed: 25.10.2017.
(check this in PDF content)
10
Statistics Netherlands (2015). StatLine [online database]. The Hague/Heerlen: Statistics Netherlands. http://statline.cbs.nl. Accessed: 25.10.2017.
(check this in PDF content)
11
Batenburg R., Kroneman M., Sagan A. The impact of the crisis on the health system and health in the Netherlands. Economic crisis, health systems and health in Europe. World Health Organization, Regional Office for Europe, European Observatory on Health Systems and Policies. 2015; URL: http://www.euro.who.int/__data/assets/pdf_ file/0010/279820/Web-economic-crisis-health-systems-and-healthweb.pdf?ua=1. Accessed: 25.10.2017.
(check this in PDF content)
12
Netherlands. Health system review. Health Systems in Transition. 2016; 18 (2): 151. URL: http://www.euro.who.int/__data/assets/pdf_ file/0016/314404/HIT_Netherlands.pdf. Accessed: 25.10.2017.
(check this in PDF content)
13
NPCF (2014). Voorlichting aan patiënt bij medicijnuitgifte nog niet in orde [Quality of information to patients at medicine delivery not yet satisfactory]. URL: https://www.patientenfederatie.nl/nieuws/ voorlichting-aan-patient-bij-medicijnuitgifte-nog-niet-in-orde. Accessed: 25.10.2017.
(check this in PDF content)
14
Griens A. M.G.F., Janssen J. M., Kroon J. D.L., Lukaart J. S., van der Vaart R. J. Data en feiten 2015. Het jaar 2014 in cijfers [Data and facts 2015. The year 2014 in figures]. The Hague: Stichting Farmaceutische Kengetallen (SFK). URL: https://www.sfk.nl/publicaties/data-en-feiten/ data-en-feiten-2015/view. Accessed: 25.10.2017.
(check this in PDF content)
15
GlobalData, Singapore’s pharmaceutical market value to reach $1.15 billion by 202. URL: https://www.globaldata.com/singaporespharmaceutical-market-value-reach-1-15-billion-2021. Accessed: 25.10.2017.
(check this in PDF content)
16
Pharmaceutical Inspection Co-operation Scheme. URL: https:// www.picscheme.org/en/members?paysselect=SG. Accessed: 25.10.2017.
(check this in PDF content)
17
GKV-Spitzenverband (2009). GKV-Arzneimittel-Schnellinformation (GAmSi). Essen, GKV-Spitzenverband. URL: http://www.gkv-gamsi.de. Accessed: 25.10.2017.
(check this in PDF content)
18
Verband der forschenden Pharma-Unternehmen (2012). General political situation. URL: https://www.vfa.de. Accessed: 25.10.2017.
(check this in PDF content)
19
Statistisches Bundesamt (2014). Statistisches jahrbuch Deutschland und Internationales. URL: https://www.destatis.de/DE/ Publikationen/StatistischesJahrbuch/StatistischesJahrbuch2014. pdf?__blob=publicationFile. Accessed: 25.10.2017.
(check this in PDF content)
20
Schaufler J., Telschow C. Arzneimittelverordnungen nach Alter und Geschlecht. In: Schwabe U., Paffrath D., eds. ArzneiverordnungsReport. 2013; 967-981. URL: https://link.springer.com/chapt er/10.1007/978-3-642-37124-0_47. Accessed: 25.10.2017.
(check this in PDF content)
21
Schaufler J., Telschow C. Überblick über die Arzneiverordnungen nach Arztgruppen. In: Schwabe U., Paffrath D., eds. ArzneiverordnungsReport 2013; 955-966. URL: https://link.springer.com/content/pdf/ bfm%3A978-3-642-37124-0%2F1.pdf. Accessed: 25.10.2017.
(check this in PDF content)
22
Bundesverband der Arzneimittel-Hersteller. Der Arzneimittelmarkt in Deutschland in Zahlen. Verordnungsmarkt und Selbstmedikation 2009. Bonn, Bundesverband der Arzneimittel-Hersteller. URL: https://www.bah-bonn.de/ bah/?type=565&file=redakteur_filesystem%2Fpublic%2Fmarkt_ zahlen_broschuere_2010.pdf. Accessed: 25.10.2017.
(check this in PDF content)
23
OECD (2013). Health data 2011, 2012, 2013. Paris, Organisation for Economic Co-operation and Development. URL: http://www.oecd. org/els/emp/. Data obrashcheniya: 25.10.2017.
(check this in PDF content)
24
Menon D., Stafinski T. Health technology assessment in Canada: 20 years strong? Value in Health. 2009; 12 (2): 14-19.
(check this in PDF content)
25
Flood C. M. The evidentiary burden for overturning government’s choice of regulatory instrument: the case of direct-to-consumer advertising of prescription drugs. University of Toronto Law Journal. 2010; 60 (2): 397-424.
(check this in PDF content)
26
Mintzes B. s soavt. Influence of direct to consumer advertising and patients’ requests on prescribing decisions: two site cross sectional survey. BMJ. 2002; 324: 278-279.
(check this in PDF content)
27
Paris V., Docteur E. Pharmaceutical pricing and reimbursement policies in Canada. Paris, (Health Working Paper). Organisation for Economic Co-operation and Development. URL: http://www.oecdilibrary.org/social-issues-migration-health/pharmaceutical-pricingand-reimbursement-policies-in-canada_346071162287?crawler=true. Accessed: 25.10.2017.
(check this in PDF content)
28
Health systems: the time of change. Review summary: Canada, 2012; European Observatory on Health Systems and Policies (in Russian). URL: http://www.euro.who.int/__data/assets/pdf_ file/0010/184672/Summary-HiT-Canada-2013-Rus.pdf?ua=1. Accessed: 26.01.2018.
(check this in PDF content)
29
Romanow R. J. Building on values: the future of health care in Canada. Saskatoon, Commission on the Future of Health Care in Canada. URL: http://publications.gc.ca/collections/Collection/CP3285-2002E.pdf. Accessed: 25.10.2017.
(check this in PDF content)
30
McMahon M., Morgan S., Mitton C. The Common Drug Review: a NICE start for Canada? Health Policy. 2006; 77 (3): 339-351.
(check this in PDF content)
31
Menon D., Stafinski T., Stuart G. Access to drugs for cancer: does where you live matter? Canadian Journal of Public Health. 2005; 96 (6): 454-458.
(check this in PDF content)
32
Grootendorst P., Hollis A. Managing pharmaceutical expenditures: overview and options for Canada. Ottawa, Canadian Health Services Research Foundation. URL: http://www.cfhi-fcass.ca/Libraries/Hospital_ Funding_docs/CHSRF-GrootendorstPharmaExpenditures.sflb.ashx. Accessed: 25.10.2017
(check this in PDF content)
33
McLeod L. et al. Financial burden of household out-of-picket expenditures for prescription drugs: cross-sectional analysis based on national survey data. Open Medicine. 2011; 5 (1): 1-9.
(check this in PDF content)
34
Pomey M. P. et al. Public/private partnerships for prescription drug coverage: policy formulation and outcomes in Quebec’s universal drug insurance program, with comparisons to the medicare Prescription Drug program. Milbank Quarterly. 2007; 85 (3): 469-498.
(check this in PDF content)
35
Romanow R. J. Building on values: the future of health care in Canada. Saskatoon, Commission on the Future of Health Care in Canada. URL: http:// www.cbc.ca/healthcare/final_report.pdf. Accessed: 25.10.2017.
(check this in PDF content)
36
Campbell B., Marchildon G. P. s soavt. Federal Pharmacare: prescription for an ailing federation? Medicare: facts, myths, problems and promise. Toronto, Lorimer. 2007; 268-284.
(check this in PDF content)
37
OECD (2014). Health at a glance: Europe 2014. London, Organisation for Economic Co-operation and Development. URL: http://www.oecd.org/els/emp/. Accessed: 25.10.2017.
(check this in PDF content)
38
OECD (2012). Pharmaceutical spending. London, Organisation for Economic Co-operation and Development. URL: http://www.oecd. org/els/emp/. Accessed: 25.10.2017.
(check this in PDF content)
39
O’Neill C., McGregor P., Merkur S. United Kingdom (Northern Ireland) health system review. Health Systems in Transition. 2012; 14 (10): 1-90.
(check this in PDF content)
40
Health & Social Care Information Centre (2014). Prescription dispensed in the community, Statistics for England, 2003-2013. URL: https://digital.nhs.uk/catalogue/PUB14414. Accessed: 25.10.2017.
(check this in PDF content)
41
Department of Health (2013). Government agrees breakthrough drug pricing deal with pharmaceutical firms. London, Department of Health. URL: https://www.gov.uk/government/news/governmentagrees-breakthrough-drug-pricing-deal-with-pharmaceutical-firms. Accessed: 25.10.2017.
(check this in PDF content)
42
Lu Y. s soavt. Medicine expenditures. In: The world medicines situation. Geneva, World Health Organization. 2010. URL: http://dosei. who.int/. Accessed: 25.10.2017. Сведения об авторах: Лукъянцева Дарья Валерьевна – к. м.н., старший научный сотрудник Центра финансов здравоохранения Научно-исследовательского
(check this in PDF content)